{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:04:52Z","timestamp":1789545892457,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"DOI":"10.7759\/cureus.116337","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:32:21Z","timestamp":1789543941000},"source":"Crossref","is-referenced-by-count":0,"title":["Exacerbation of Pre-existing Hypothyroidism Following Enarodustat Administration in a Patient on Peritoneal Dialysis: A Case Report"],"prefix":"10.7759","author":[{"given":"Kiho","family":"Yanagisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Sakurabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genichi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Hanyuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Uchitsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayumi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.06.005","article-title":"Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)","volume":"109","author":"Babitt JL","year":"2026","unstructured":"Babitt JL, Berns JS, Bozkurt B, et al.. Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int. 2026, 109:44-56. 10.1016\/j.kint.2025.06.005","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2025.10.017","article-title":"Navigating anemia therapy in CKD with hypoxia-inducible factor activators: a review","volume":"87","author":"Haase VH","year":"2026","unstructured":"Haase VH, Costa NA, Koury MJ. Navigating anemia therapy in CKD with hypoxia-inducible factor activators: a review. Am J Kidney Dis. 2026, 87:716-29. 10.1053\/j.ajkd.2025.10.017","journal-title":"Am J Kidney Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13820","article-title":"Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: a review of the evidence","volume":"26","author":"Fujikawa R","year":"2022","unstructured":"Fujikawa R, Nagao Y, Fujioka M, Akizawa T. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: a review of the evidence. Ther Apher Dial. 2022, 26:679-93. 10.1111\/1744-9987.13820","journal-title":"Ther Apher Dial"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial","volume":"15","author":"Akizawa T","year":"2020","unstructured":"Akizawa T, Nangaku M, Yonekawa T, et al.. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clin J Am Soc Nephrol. 2020, 15:1155-65. 10.2215\/CJN.16011219","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad250","article-title":"Anaemia in CKD-treatment standard","volume":"39","author":"Macdougall IC","year":"2024","unstructured":"Macdougall IC. Anaemia in CKD-treatment standard. Nephrol Dial Transplant. 2024, 39:770-7. 10.1093\/ndt\/gfad250","journal-title":"Nephrol Dial Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02304-2","article-title":"Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis","volume":"22","author":"Ichii M","year":"2021","unstructured":"Ichii M, Mori K, Miyaoka D, et al.. Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis. BMC Nephrol. 2021, 22:104. 10.1186\/s12882-021-02304-2","journal-title":"BMC Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab007","article-title":"Roxadustat and thyroid-stimulating hormone suppression","volume":"14","author":"Tokuyama A","year":"2021","unstructured":"Tokuyama A, Kadoya H, Obata A, Obata T, Sasaki T, Kashihara N. Roxadustat and thyroid-stimulating hormone suppression. Clin Kidney J. 2021, 14:1472-4. 10.1093\/ckj\/sfab007","journal-title":"Clin Kidney J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76499","article-title":"Roxadustat-induced central hypothyroidism masked by uremia at the initiation of hemodialysis: a case report","volume":"16","author":"Hashimoto M","year":"2024","unstructured":"Hashimoto M, Nagayama Y, Ichikura-Iida A, Inoue T. Roxadustat-induced central hypothyroidism masked by uremia at the initiation of hemodialysis: a case report. Cureus. 2024, 16:e76499. 10.7759\/cureus.76499","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.10.002","article-title":"Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance","volume":"20","author":"Yao B","year":"2019","unstructured":"Yao B, Wei Y, Zhang S, et al.. Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance. iScience. 2019, 20:489-96. 10.1016\/j.isci.2019.10.002","journal-title":"iScience"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-025-04863-x","article-title":"Associations of roxadustat with copper elevation and hypothyroidism in patients on hemodialysis: a critical appraisal","volume":"58","author":"Batool S","year":"2026","unstructured":"Batool S, Amjad M, Madni A. Associations of roxadustat with copper elevation and hypothyroidism in patients on hemodialysis: a critical appraisal. Int Urol Nephrol. 2026, 58:2329-30. 10.1007\/s11255-025-04863-x","journal-title":"Int Urol Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2410375","article-title":"Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study","volume":"46","author":"Otsuka E","year":"2024","unstructured":"Otsuka E, Kitamura M, Funakoshi S, Mukae H, Nishino T. Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study. Ren Fail. 2024, 46:2410375. 10.1080\/0886022X.2024.2410375","journal-title":"Ren Fail"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad483","article-title":"Effect of roxadustat on thyroid function in patients with renal anemia","volume":"109","author":"Haraguchi T","year":"2023","unstructured":"Haraguchi T, Hamamoto Y, Kuwata H, et al.. Effect of roxadustat on thyroid function in patients with renal anemia. J Clin Endocrinol Metab. 2023, 109:e69-75. 10.1210\/clinem\/dgad483","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2378903","article-title":"A spotlight on using HIF-PH inhibitors in renal anemia","volume":"25","author":"Odawara M","year":"2024","unstructured":"Odawara M, Nishi H, Nangaku M. A spotlight on using HIF-PH inhibitors in renal anemia. Expert Opin Pharmacother. 2024, 25:1291-9. 10.1080\/14656566.2024.2378903","journal-title":"Expert Opin Pharmacother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a\u00a0potential new treatment for anemia in patients with CKD","volume":"69","author":"Gupta N","year":"2017","unstructured":"Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a\u00a0potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017, 69:815-26. 10.1053\/j.ajkd.2016.12.011","journal-title":"Am J Kidney Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.110397","article-title":"Non-thyroidal illness syndrome as an adaptive longevity program: reframing low T3 in acute and chronic disease","volume":"18","author":"Mazza AD","year":"2026","unstructured":"Mazza AD. Non-thyroidal illness syndrome as an adaptive longevity program: reframing low T3 in acute and chronic disease. Cureus. 2026, 18:e110397. 10.7759\/cureus.110397","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.110424","article-title":"Non-thyroidal illness syndrome and clinical outcomes in critically ill ICU patients: a prospective cohort study","volume":"18","author":"Rabi R","year":"2026","unstructured":"Rabi R, Ismail I, Safa M, Odeh A, Marmash K, Abugaber D. Non-thyroidal illness syndrome and clinical outcomes in critically ill ICU patients: a prospective cohort study. Cureus. 2026, 18:e110424. 10.7759\/cureus.110424","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76715","article-title":"Thyroid dysfunction in patients with end-stage renal disease: a single-centered experience from Pakistan","volume":"17","author":"German S","year":"2025","unstructured":"German S, Bhatti S, Waqar T, et al.. Thyroid dysfunction in patients with end-stage renal disease: a single-centered experience from Pakistan. Cureus. 2025, 17:e76715. 10.7759\/cureus.76715","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10040245","article-title":"Thyroid pathology in end-stage renal disease patients on hemodialysis","volume":"10","author":"Cotoi L","year":"2020","unstructured":"Cotoi L, Borcan F, Sporea I, et al.. Thyroid pathology in end-stage renal disease patients on hemodialysis. Diagnostics (Basel). 2020, 10:245. 10.3390\/diagnostics10040245","journal-title":"Diagnostics (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.75459","article-title":"HIF-1\u03b1\/YAP signaling rewrites glucose\/iodine metabolism program to promote papillary thyroid cancer progression","volume":"19","author":"Song H","year":"2023","unstructured":"Song H, Qiu Z, Wang Y, et al.. HIF-1\u03b1\/YAP signaling rewrites glucose\/iodine metabolism program to promote papillary thyroid cancer progression. Int J Biol Sci. 2023, 19:225-41. 10.7150\/ijbs.75459","journal-title":"Int J Biol Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14051126","article-title":"Current studies on the hypoxic tumor microenvironment in thyroid cancer: from molecular mechanisms to clinical therapeutic perspectives","volume":"14","author":"Peng X","year":"2026","unstructured":"Peng X, Ma L, Chang W. Current studies on the hypoxic tumor microenvironment in thyroid cancer: from molecular mechanisms to clinical therapeutic perspectives. Biomedicines. 2026, 14:1126. 10.3390\/biomedicines14051126","journal-title":"Biomedicines"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3892\/or.2016.5228","article-title":"Inhibiting \u03b2-catenin expression promotes efficiency of radioiodine treatment in aggressive follicular thyroid cancer cells probably through mediating NIS localization","volume":"37","author":"Lan L","year":"2017","unstructured":"Lan L, Basourakos S, Cui D, et al.. Inhibiting \u03b2-catenin expression promotes efficiency of radioiodine treatment in aggressive follicular thyroid cancer cells probably through mediating NIS localization. Oncol Rep. 2017, 37:426-34. 10.3892\/or.2016.5228","journal-title":"Oncol Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/531323-exacerbation-of-pre-existing-hypothyroidism-following-enarodustat-administration-in-a-patient-on-peritoneal-dialysis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:32:22Z","timestamp":1789543942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/531323-exacerbation-of-pre-existing-hypothyroidism-following-enarodustat-administration-in-a-patient-on-peritoneal-dialysis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.116337","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}